Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis

Since starting omalizumab, he is no longer taking doxepin and has reduced his dose of Advair 250/50Â Î¼g to 100/50 Î¼g (GlaxoSmithKline, Research Triangle Park, NC). At age 48 years, he had another severe episode of anaphylaxis requiring an intensive care unit admission. Since age 48 years, he has h...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of allergy and clinical immunology 2007-06, Vol.119 (6), p.1550-1551
Hauptverfasser:	Carter, Melody C., MD, Robyn, Jamie A., MD, PhD, Bressler, Peter B., MD, Walker, John C., MD, Shapiro, Gail G., MD, Metcalfe, Dean D., MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Age Allergies Allergy and Immunology Anaphylaxis - drug therapy Anaphylaxis - immunology Anaphylaxis - pathology Anti-Allergic Agents - therapeutic use Antibodies, Anti-Idiotypic Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Asthma Diarrhea Family medical history Hospitalization Humans Male Mastocytosis, Systemic - drug therapy Mastocytosis, Systemic - immunology Mastocytosis, Systemic - pathology Middle Aged Mutation Omalizumab Patients Receptors, IgE - antagonists & inhibitors Urticaria Pigmentosa - drug therapy Urticaria Pigmentosa - immunology Urticaria Pigmentosa - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Since starting omalizumab, he is no longer taking doxepin and has reduced his dose of Advair 250/50Â Î¼g to 100/50 Î¼g (GlaxoSmithKline, Research Triangle Park, NC). At age 48 years, he had another severe episode of anaphylaxis requiring an intensive care unit admission. Since age 48 years, he has had 15 to 16 episodes of anaphylaxis per year and during these episodes has associated wheezing, vomiting, and hives, but no angioedema.
ISSN:	0091-6749 1097-6825
DOI:	10.1016/j.jaci.2007.03.032